活血消瘿方治疗结节性甲状腺肿55例

Clinical Research of Huoxue Xiaoying Fang on Nodular Goiter

目的探讨活血消瘿方治疗结节性甲状腺肿的临床疗效,并分析其作用机制。方法选取南京中医药大学附属医院2012年1月至2013年12月间110例结节性甲状腺肿患者为研究对象,按照随机数字表法分为治疗组55例和对照组55例,对照组给予常规的优甲乐治疗,治疗组给予活血消瘿方治疗,观察2组的治疗效果。结果治疗组总有效率为90.9%,对照组总有效率为69.1%,治疗组明显高于对照组(P<0.05);除对照组治疗后TSH较治疗前有明显的降低(P<0.05)外,2组FT3、FT4治疗前后比,均P>0.05。2组治疗后IGF-1较治疗前有明显的降低,TGF-β1较治疗前有明显的升高,P<0.05,治疗组优于对照组,P<0.05;治疗组不良反应发生率为0;对照组不良反应发生率为16.4%,2组比较,P<0.05。结论应用活血消瘿方治疗甲状腺肿效果显著,主要是通过调节相关因子达到治疗效果,不良反应少,值得临床中应用与推广。

OBJECTIVE To discuss the clinical effects of Huoxue Xiaoying Fang on treating nodular goiter and to analyze its mechanism of action.METHODS 110 cases with nodular goiter were selected from the Affiliated Hospital of Nanjing University of Chinese Medicine from January 2012 to December 2013 for study,which were divided into research group treated by Euthyrox and control group treated by Huoxue Xiaoying Fang by random number table method,to observe the effect.RESULTS The total effective rate in research group was 90.9 % but 69.1%in the control group.The total efficacy in the research group was significantly higher than that of the control group （P〈0.05）.FT3,FT4 and TSH in research group had no significant difference before and after treatment （P〉0.05）.FT3 and FT4 in the control group before and after treatment had no significant differences （P〉0.05）.Compared with that before treatment,TSH after treatment in control treatment decreased significantly （P〈0.05） with the differences showing statistical significance.Compared with that before treatment,the IGF-Ⅰ after treatment had significantly lowered while the TGF-β1 increased significantly.The comparative differences of data were statistically significant （P〈0.05）.The incidence of adverse reaction research group was 0 but 16.4 % in control group（P〈0.05）.when compared between the two groups.CONCLUSION The clinical effect of Huoxue Xiaoying Fang on goiter is significant in clinic,so as to achieve the effect of clinical treatment mainly by regulating the relevant factors,with less adverse reactions and worthy of clinical application and promotion.